U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239544) titled 'Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines' on Nov. 16.
Brief Summary: Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.
Study Start Date: July 10
Study Type: OBSERVATIONAL
Condition:
Lung Cancer (NSCLC)
Intervention:
OTHER: observational study
observational study:Evaluate the broad-spectrum coverage of xenogeneic hybrid lung cancer antigens (including patient tissues and cell lines), and develop a universal whole-cell antigen nanode...